Next Phase Newsletter

A California-based private investment firm funded by a single LP invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. The firm is agnostic in terms of subsectors and indications, including orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm takes a board seat in some cases, and prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund created in 2013 and based in Canada with connections to the European market is looking for companies located in Canada and the United States. The firm makes equity investments in progressive stages, ranging between 500k – $5m and typically leads the round – although the firm is open to co-investing. The firm is interested in pre-revenue companies within one year of generating revenue, all the way up to expansion stage.

The firm is interested in anything with a technology aspect – including medical devices, diagnostics, healthcare IT, industrial & telecom. The firm is not interested in drug discovery and is open to all indication areas. The firm will consider regulatory devices and looks for technologies with a strong competitive advantage.

The firm looks for companies led by strong, experienced and capable teams as the firm makes minority stake investments. The firm looks for management teams who understand the regulatory and competitive landscape and are familiar with their chosen subsector and indication area. Although the firm looks for companies backed by strong technology, the firm puts more emphasis on management team capabilities and will not invest in a company unless this requirement is met. The firm takes a board seat on all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chinese venture capital firm with offices in Shanghai and Beijing has raised two funds to date, with its second fund raised in 2011 at USD 125 million. The firm mainly invests in early stage high-growth technology businesses but has expanded its interest into medical technology. The firm generally allocates USD 5-10 million per company, and focuses 70% domestically and 30% on the US. The firm is interested in companies that have a China angle, specifically, developing products relevant to the Chinese market. The firm is actively seeking new investment opportunities.

In healthcare, the firm is currently looking for medical devices that address a large market in China. IVD and devices with a software component are of high interest. The firm is opportunistic in terms of subsectors and considers all classes of devices. In terms of the stage of development, the firm prefers devices that have regulatory approval (preferably CE mark); ideally, the device should be ready for CFDA. However, the firm will also consider devices in the final stages of clinical trials.

The firm can invest globally but the firm is only interested in companies that have a China angle, i.e. Chinese-led and/or developing products for the Chinese market. The firm has no revenue requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage healthcare technology venture capital investment firm based in Boston, Massachusetts recently raised $200 million for its first dedicated healthcare technology-focused fund in 2015. The firm primarily invests in companies in the seed, series A and B stages targeting healthcare technology and services and is seeking 8-10 new investments within the next year. The firm typically invests an initial range of $500K-$5M and may go up to investing $10M-$15M per company overall, though the size may vary depending on the opportunity. The firm primarily invests in companies based in the US, though is open to companies on a global level. The firm seeks to be a significant investor in any of its portfolio companies and will often serve on the boards of those companies.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and services sectors with a specific focus on healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare and leverage wireless, data and analytics technologies. The firm currently is not focused on therapeutics or medical device investment opportunities, though has interest in medical devices with a software/data component, such as sensors. The firm may be open to 510K devices, however, it is not interested in PMA devices. The firm is indication agnostic and invests only in pre-revenue early stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in California with additional offices throughout the USA and Asia invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. The firm has a large fund that invests only in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is not currently seeking opportunities in diagnostics. In biopharma, the firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage. In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets. The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space. The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment fund offers business training programs for early stage ventures solving global challenges within several fields, including healthcare. The firm typically works with companies who have received less than $1 million in institutional funding and are looking to raise $500K or more in the next 12-18 months. In each program, 12innovative ventures are selected to participate, and among them, two will receive $50,000 investment each through a peer-selection process. The US-based programs are open to companies that are US-based, serving the US market, or with presence in the US.

Within healthcare, the firm is interested in entrepreneurs with solutions that will increase and/or improve access to both healthcare and treatment for low-wealth individuals. Examples may include healthcare IT solutions or innovative medtech and diagnostic tools. The program seeks companies that have developed some sort of traction, either revenue-based or meaningful customer feedback, user acquisition, successful pilots, or strategic partnerships.

The firm looks at experience, competency, and the overall dynamic of management teams. To participate in the business-training programs, the company must have at least one full time team member.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Shanghai, China, provides growth/expansion capital to companies with validated business models, with investments typically ranging from $10M-$100M. Investments are made into mature companies ready for an IPO within 12-18 months or earlier-stage companies with platform technologies or a broad portfolio of assets, especially therapeutics/devices/technologies that would be applicable to the Asian market. Minority or majority equity investments are made in selected companies.

As for earlier-stage companies, the firm is opportunistic in terms of sector and is open to therapeutics, medical devices and healthcare IT companies, but prefers to invest in companies with products on the market. Companies with a platform technology capable of generating several assets or a broad portfolio targeting different indications are more likely to be considered. Software-based or other Health IT oriented companies should have considerable traction, proving that their business model is viable. One of the firm’s past investments includes a biologic’s CMO.

The firm invest in companies based in the U.S. or China, and requires companies that have a proven business model, as they provide expansion capital and access to an extensive network of advisors, industry executives and business relationships to provide portfolio companies support from financial and strategic angels. Board representation is typically required along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com